Suppr超能文献

对局部晚期宫颈癌患者进行顺铂和异环磷酰胺同步放化疗后巩固化疗的长期随访。

Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy.

作者信息

Petrić Miše Branka, Boraska Jelavić Tihana, Strikic Ante, Hrepić Darijo, Tomić Krešimir, Hamm Wolfgang, Tomić Snježana, Prskalo Tomislav, Vrdoljak Eduard

机构信息

*Department of Oncology, University Hospital Split, Split, Croatia; †Department of Oncology, University Hospital Mostar, Mostar, Bosnia and Herzegovina; ‡Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; and §Department of Pathology, University Hospital Split, Split, Croatia.

出版信息

Int J Gynecol Cancer. 2015 Feb;25(2):315-9. doi: 10.1097/IGC.0000000000000336.

Abstract

OBJECTIVES

Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries. We present long-term outcomes of treatment with a concomitant chemobrachyradiotherapy followed by consolidation chemotherapy regimen.

MATERIALS AND METHODS

We treated 118 patients with LACC (International Federation of Gynecology and Obstetrics stages IB2-IVA) with external radiotherapy (50 Gy in 25 fractions) and concomitant chemobrachyradiotherapy (low-dose rate). Chemotherapy was applied during brachyradiotherapy (cisplatin on day 1 in combination with 24-hour infusion of ifosfamide and mesna uroprotection). Four cycles of consolidation chemotherapy were given starting 4 weeks after the second concomitant chemobrachyradiotherapy cycle.

RESULTS

After median follow-up period of 99.3 months, we observed acceptable acute and late toxicity, local control rate of 97.5%, and an overall survival of 74.6% at 96 months.

CONCLUSIONS

Chemobrachyradiotherapy regimen followed by consolidation chemotherapy described in this article is a valuable treatment option for LACC.

摘要

目的

局部晚期宫颈癌(LACC)是发展中国家主要的健康问题之一。我们报告了同步放化疗联合巩固化疗方案治疗的长期结果。

材料与方法

我们对118例LACC患者(国际妇产科联盟分期为IB2-IVA期)进行了外照射放疗(25次分割,共50 Gy)和同步近距离化疗(低剂量率)。在近距离放疗期间进行化疗(第1天给予顺铂,联合24小时输注异环磷酰胺和美司钠进行尿路保护)。在第二个同步近距离化疗周期后4周开始给予4个周期的巩固化疗。

结果

中位随访99.3个月后,我们观察到可接受的急性和晚期毒性,局部控制率为97.5%,96个月时总生存率为74.6%。

结论

本文所述的同步放化疗联合巩固化疗方案是LACC的一种有价值的治疗选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验